Latest Insider Transactions at Entrada Therapeutics, Inc. (TRDA)
This section provides a real-time view of insider transactions for Entrada Therapeutics, Inc. (TRDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entrada Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entrada Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2023
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,200
+22.27%
|
-
|
|
Sep 01
2023
|
Nerissa Kreher Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,200
+25.57%
|
-
|
|
Aug 14
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.49%
|
$15,000
$15.67 P/Share
|
|
Aug 04
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,898
-20.27%
|
$96,572
$14.14 P/Share
|
|
Aug 04
2023
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,898
+16.85%
|
$13,796
$2.1 P/Share
|
|
Aug 03
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,464
-25.86%
|
$132,496
$14.74 P/Share
|
|
Aug 03
2023
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,464
+20.55%
|
$18,928
$2.1 P/Share
|
|
Aug 02
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,348
-9.52%
|
$155,220
$15.97 P/Share
|
|
Aug 02
2023
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,348
+21.64%
|
$20,696
$2.1 P/Share
|
|
Jul 11
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,884
-9.56%
|
$69,912
$18.0 P/Share
|
|
Jul 11
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,884
+8.73%
|
$7,768
$2.1 P/Share
|
|
Jul 11
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
14,852
-8.82%
|
$267,336
$18.04 P/Share
|
|
Jul 11
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
3,897
-9.92%
|
$70,146
$18.05 P/Share
|
|
Jul 10
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,116
-14.27%
|
$103,972
$17.98 P/Share
|
|
Jul 10
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,116
+12.49%
|
$12,232
$2.1 P/Share
|
|
Jul 10
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
3,026
-1.77%
|
$54,468
$18.0 P/Share
|
|
Jul 10
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
3,200
-7.53%
|
$57,600
$18.0 P/Share
|
|
Jun 29
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,790
+19.3%
|
$17,580
$2.1 P/Share
|
|
Jun 22
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
7,097
-14.32%
|
$113,552
$16.02 P/Share
|
|
Jun 21
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,500
-21.53%
|
$262,500
$15.01 P/Share
|
|
Jun 21
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+27.8%
|
$35,000
$2.1 P/Share
|
|
Jun 20
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
8,885
-15.2%
|
$124,390
$14.94 P/Share
|
|
Apr 27
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-0.98%
|
$26,000
$13.71 P/Share
|
|
Apr 17
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
3,961
-2.26%
|
$71,298
$18.0 P/Share
|
|
Apr 17
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,092
-1.01%
|
$37,656
$18.01 P/Share
|
|
Mar 27
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-0.39%
|
$30,000
$15.07 P/Share
|
|
Mar 02
2023
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,028
-1.4%
|
$11,308
$11.6 P/Share
|
|
Mar 02
2023
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,324
-1.27%
|
$36,564
$11.6 P/Share
|
|
Mar 02
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,058
-0.56%
|
$11,638
$11.6 P/Share
|
|
Mar 02
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,747
-2.0%
|
$17,470
$10.85 P/Share
|
|
Mar 02
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,005
-2.24%
|
$11,055
$11.6 P/Share
|
|
Mar 02
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,641
-1.92%
|
$16,410
$10.86 P/Share
|
|
Mar 02
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
945
-2.15%
|
$10,395
$11.6 P/Share
|
|
Mar 01
2023
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
28,400
+27.82%
|
-
|
|
Mar 01
2023
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
99,300
+27.55%
|
-
|
|
Mar 01
2023
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
28,400
+12.97%
|
-
|
|
Mar 01
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,400
+38.74%
|
-
|
|
Mar 01
2023
|
Nerissa Kreher Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,400
+39.27%
|
-
|
|
Feb 28
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-1.22%
|
$24,000
$12.0 P/Share
|
|
Jan 27
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-1.21%
|
$24,000
$12.0 P/Share
|
|
Jan 09
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,410
-1.43%
|
$36,150
$15.02 P/Share
|
|
Dec 30
2022
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,200
-25.1%
|
$67,600
$13.45 P/Share
|
|
Dec 29
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
400
-0.24%
|
$6,000
$15.01 P/Share
|
|
Dec 28
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
4,521
-2.61%
|
$67,815
$15.01 P/Share
|
|
Dec 27
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
9,669
-2.65%
|
$135,366
$14.92 P/Share
|
|
Dec 08
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,550
-21.61%
|
$81,900
$18.95 P/Share
|
|
Dec 08
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,550
+17.77%
|
$9,100
$2.1 P/Share
|
|
Dec 05
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-1.2%
|
$3,600
$18.05 P/Share
|
|
Dec 05
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.18%
|
$400
$2.1 P/Share
|
|
Dec 02
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,910
-14.99%
|
$52,380
$18.2 P/Share
|